Monsonet M, Rockwood NJ, Kwapil TR, Barrantes-Vidal N. Psychological pathways to paranoia and psychotic-like experiences in daily-life: the mediating role of distinct affective disturbances. Schizophr Bull. 2022 Sep 1;48(5):1053-65. doi: 10.1093/schbul/sbac071
Groskaufmanis L, Lin P, Kamdar N, Khan A, Peterson MD, Meade M, Mahmoudi E. Racial and ethnic inequities in use of preventive services among privately insured adults with a pediatric-onset disability. Ann Fam Med. 2022 Sep;20(5):430-7. doi: 10.1370/afm.2849
Van Scoy LJ, Miller EL, Snyder B, Wasserman E, Chinchilli VM, Zgierska AE, Rabago D, Lennon CL, Lipnick D, Toyobo O, Ruffin 4th MT, Lennon RP. Knowledge, perceptions, and preferred information sources related to COVID-19 among central Pennsylvania adults early in the pandemic: a mixed methods cross-sectional survey. Ann Fam Med. 2021 Jul;19(4):293-301. doi: 10.1370/afm.2674
Andrews S, Mansfield C, O'Neill C, Peay H. Meaningful treatment outcomes for Sanfilippo syndrome: using a combination of focus groups and best-worst scaling to elicit and explore parents' priorities. Poster presented at the 2019 25th Annual Qualitative Health Research Conference; October 2019. Vancouver, Canada. [abstract] Int J Qual Methods. 2020 Mar 30; 19:2. doi: 10.1177/1609406920909934
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Cheraghi-Sohi S, Hole AR, Mead N, McDonald R, Whalley D, Bower P, Roland M. What patients want from primary care consultations: a discrete choice experiment to identify patients' priorities. Ann Fam Med. 2008 Mar 15;6(2):107-15.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.